• Explore /
  • Poster
  • / A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC‑1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.

A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC‑1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following disease progression (PD) on docetaxel (DCT) therapy.

Abstract Poster

Authors

Maha Hussain

Maha Hussain

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

Maha Hussain , Dana E. Rathkopf , Glenn Liu , Andrew J. Armstrong , William Kevin Kelly , Anna C. Ferrari , John D. Hainsworth , Ling Yang , Jonathan D. Schwartz , Celestia S. Higano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT00683475

Citation

J Clin Oncol 30, 2012 (suppl 5; abstr 97)

DOI

10.1200/jco.2012.30.5_suppl.97

Abstract #

97

Poster Bd #

B2

Abstract Disclosures

Similar Posters

First Author: Susan Halabi

First Author: K. N. Chi

First Author: Daniel J. George

First Author: Teresa Alonso Gordoa